The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia

Leukemia

Volumn 31, Issue 2, 2017, Pages 470-478

  Qorraj, M ^a   Bruns, H ^a   Bottcher M ^a   Weigand, L ^a   Saul, D ^a   Mackensen, A ^a   Jitschin, R ^a   Mougiakakos, D ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; CD11B ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; COLONY STIMULATING FACTOR 1; ENOLASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; LACTATE DEHYDROGENASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PYRUVATE DEHYDROGENASE KINASE; TUMOR NECROSIS FACTOR; AGAMMAGLOBULINAEMIA TYROSINE KINASE; BIOLOGICAL MARKER; GLUCOSE; PROTEIN BINDING; PROTEIN TYROSINE KINASE;

ARTICLE; CARBOHYDRATE METABOLISM; CELL METABOLISM; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; EXTRACELLULAR SPACE; GENE EXPRESSION; GLUCOSE INTAKE; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MONOCYTE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ENERGY METABOLISM; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANTIGENS, CD274; BIOMARKERS; ENERGY METABOLISM; GLUCOSE; GLYCOLYSIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MONOCYTES; PHAGOCYTOSIS; PHENOTYPE; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84984843599     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.214     Document Type: Article

References (67)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Morrison VA. The infectious complications of chronic lymphocytic leukemia. Semin Oncol 1998; 25: 98-106.
3. Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood 2015; 126: 573-581.
4. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118: 2427-2437.
5. Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 2013; 98: 953-963.
6. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018-2025.
7. Jurado-Camino T, Cordoba R, Esteban-Burgos L, Hernandez-Jimenez E, Toledano V, Hernandez-Rivas JA et al. Chronic lymphocytic leukemia: a paradigm of innate immune cross-tolerance. J Immunol 2015; 194: 719-727.
8. Maffei R, Bulgarelli J, Fiorcari S, Bertoncelli L, Martinelli S, Guarnotta C et al. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica 2013; 98: 1115-1123.
9. Jitschin R, Braun M, Buttner M, Dettmer-Wilde K, Bricks J, Berger J et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 2014; 124: 750-760.
10. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331: 1612-1616.
11. Bruns H, Buttner M, Fabri M, Mougiakakos D, Bittenbring JT, Hoffmann MH et al. Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma. Sci Transl Med 2015; 7: 282ra247.
12. Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 2014; 156: 590-602.
13. Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol 2014; 32: 3039-3047.
14. Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. MAbs 2015; 7: 303-310.
15. Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 2015; 162: 1229-1241.
16. Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 2014; 345: 1250684.
17. Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. Cell Metab 2012; 15: 432-437.
18. Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 2015; 125: 3905-3916.
19. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 2015; 6: 6692.
20. McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D et al. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Emicro-TCL1 CLL mouse model. Blood 2015; 126: 212-221.
21. McClanahan F, Hanna B, Miller S, Clear AJ, Lichter P, Gribben JG et al. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood 2015; 126: 203-211.
22. Schmidl C, Renner K, Peter K, Eder R, Lassmann T, Balwierz PJ et al. Transcription and enhancer profiling in human monocyte subsets. Blood 2014; 123: e90-e99.
23. Palmer CS, Anzinger JJ, Zhou J, Gouillou M, Landay A, Jaworowski A et al. Glucose transporter 1-expressing proinflammatory monocytes are elevated in combination antiretroviral therapy-treated and untreated HIV+ subjects. J Immunol 2014; 193: 5595-5603.
24. Izquierdo E, Cuevas VD, Fernandez-Arroyo S, Riera-Borrull M, Orta-Zavalza E, Joven J et al. Reshaping of human macrophage polarization through modulation of glucose catabolic pathways. J Immunol 2015; 195: 2442-2451.
25. Tan Z, Xie N, Cui H, Moellering DR, Abraham E, Thannickal VJ et al. Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism. J Immunol 2015; 194: 6082-6089.
26. Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005; 142: 481-489.
27. Sbarra AJ, Karnovsky ML. The biochemical basis of phagocytosis. I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. J Biol Chem 1959; 234: 1355-1362.
28. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptordependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199: 1659-1669.
29. Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 2008; 112: 1205-1213.
30. Dimitriadis G, Maratou E, Boutati E, Psarra K, Papasteriades C, Raptis SA. Evaluation of glucose transport and its regulation by insulin in human monocytes using flow cytometry. Cytometry A 2005; 64: 27-33.
31. Kragballe K, Beck-Nielsen H, Pedersen O, Ellegaard J, Sorensen NS. Monocytemediated antibody-dependent cytotoxicity. Modulation by glycolysis and insulin. Scand J Haematol 1981; 26: 137-144.
32. Church AK, VanDerMeid KR, Baig NA, Baran AM, Witzig TE, Nowakowski GS et al. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages. Clin Exp Immunol 2016; 183: 90-101.
33. Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S et al. Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor bearing hosts by ibrutinib treatment. Cancer Res 2016; 76: 2125-2136.
34. Futatani T, Miyawaki T, Tsukada S, Hashimoto S, Kunikata T, Arai S et al. Deficient expression of Bruton's tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection. Blood 1998; 91: 595-602.
35. Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 2011; 7: 41-50.
36. Doughty CA, Bleiman BF, Wagner DJ, Dufort FJ, Mataraza JM, Roberts MF et al. Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth. Blood 2006; 107: 4458-4465.
37. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci USA 2009; 106: 6303-6308.
38. Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med 2010; 16: 452-459.
39. Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013; 121: 1612-1621.
40. Giannoni P, Pietra G, Travaini G, Quarto R, Shyti G, Benelli R et al. Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica 2014; 99: 1078-1087.
41. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33: 375-386.
42. Chung J, Serezani CH, Huang SK, Stern JN, Keskin DB, Jagirdar R et al. Rap1 activation is required for Fc gamma receptor-dependent phagocytosis. J Immunol 2008; 181: 5501-5509.
43. Taylor RP, Lindorfer MA. Antigenic modulation and rituximab resistance. Semin Hematol 2010; 47: 124-132.
44. Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science 2013; 342: 1242454.
45. Zhao E, Maj T, Kryczek I, Li W, Wu K, Zhao L et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol 2016; 17: 95-103.
46. Huang SC, Everts B, Ivanova Y, O'Sullivan D, Nascimento M, Smith AM et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol 2014; 15: 846-855.
47. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol 2011; 186: 3299-3303.
48. O'Neill LA, Pearce EJ. Immunometabolism governs dendritic cell and macrophage function. J Exp Med 2016; 213: 15-23.
49. Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T et al. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood 2015; 125: 111-123.
50. Guminska M, Ptak W, Zembala M. Macrophage metabolism during phagocytosis and digestion of normal and IgG antibody-coated sheep erythrocytes. Enzyme 1975; 19: 24-37.
51. Ayre SG, Perez Garcia y Bellon D, Perez Garcia D Jr. Neoadjuvant low-dose chemotherapy with insulin in breast carcinomas. Eur J Cancer 1990; 26: 1262-1263.
52. Saiya-Cork K, Collins R, Parkin B, Ouillette P, Kuizon E, Kujawski L et al. A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. Clin Cancer Res 2011; 17: 2679-2692.
53. Fiorcari S, Martinelli S, Bulgarelli J, Audrito V, Zucchini P, Colaci E et al. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Haematologica 2015; 100: 253-262.
54. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008; 14: 4650-4657.
55. Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MA, Sheedy FJ, Gleeson LE et al. Pyruvate kinase M2 regulates Hif-1alpha activity and IL-1beta induction and is a critical determinant of the Warburg effect in LPS-activated macrophages. Cell Metab 2015; 21: 65-80.
56. Jongstra-Bilen J, Puig Cano A, Hasija M, Xiao H, Smith CI, Cybulsky MI. Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. J Immunol 2008; 181: 288-298.
57. Da Roit F, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica 2015; 100: 77-86.
58. Skarzynski M, Niemann CU, Lee YS, Martyr S, Maric I, Salem D et al. Interactions between ibrutinib and anti-CD20 antibodies: competing effects on the outcome of combination therapy. Clin Cancer Res 2016; 22: 86-95.
59. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
60. MacFarlane AWt, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S et al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2014; 2: 320-331.
61. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domaincontaining tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 2001; 98: 13866-13871.
62. Hajduch E, Alessi DR, Hemmings BA, Hundal HS. Constitutive activation of protein kinase B alpha by membrane targeting promotes glucose and system A amino acid transport, protein synthesis, and inactivation of glycogen synthase kinase 3 in L6 muscle cells. Diabetes 1998; 47: 1006-1013.
63. Hernandez R, Teruel T, Lorenzo M. Akt mediates insulin induction of glucose uptake and up-regulation of GLUT4 gene expression in brown adipocytes. FEBS Lett 2001; 494: 225-231.
64. Helliwell PA, Rumsby MG, Kellett GL. Intestinal sugar absorption is regulated by phosphorylation and turnover of protein kinase C betaII mediated by phosphatidylinositol 3-kinase- and mammalian target of rapamycin-dependent pathways. J Biol Chem 2003; 278: 28644-28650.
65. Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab 2014; 20: 61-72.
66. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014; 211: 781-790.
67. Krause DS, Scadden DT. A hostel for the hostile: the bone marrow niche in hematologic neoplasms. Haematologica 2015; 100: 1376-1387.